CEL-SCI (CEL-SCI) Long-Term Capital Lease Obligation : $11.07 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Long-Term Capital Lease Obligation?

CEL-SCI's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.07 Mil.

CEL-SCI's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($12.11 Mil) to Sep. 2023 ($11.60 Mil) and declined from Sep. 2023 ($11.60 Mil) to Dec. 2023 ($11.07 Mil).

CEL-SCI's annual Long-Term Capital Lease Obligation declined from Sep. 2021 ($15.27 Mil) to Sep. 2022 ($13.57 Mil) and declined from Sep. 2022 ($13.57 Mil) to Sep. 2023 ($11.60 Mil).

CEL-SCI Long-Term Capital Lease Obligation Historical Data

The historical data trend for CEL-SCI's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Long-Term Capital Lease Obligation Chart

CEL-SCI Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

13.51

12.87

15.27

13.57

11.60

CEL-SCI Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															13.10	12.61	12.11	11.60	11.07

CEL-SCI (AMEX:CVM) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

CEL-SCI Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CEL-SCI (CEL-SCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

LSRM:Germany LSRM:Germany

Address

8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182

Website

https://www.cel-sci.com

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Executives

Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano	officer: Senior Vice President	8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson	director	245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine	director	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor	officer: Chief Scientific Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten	director, officer: Chief Executive Officer	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman	officer: Sr. Vice President, Research	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep	officer: Sr. Vice President, Operations	8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De	director, officer: President
C Richard Kinsolving	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy	director	8229 BOONE BLVD, STE 802, VIENNA VA 22182